Those diagnosed with cancer or with a past history of it
Sugatani J, Miwa M, Komiyama Y, Ito S
In parallel, the SURMOUNT trials, which focused on individuals with obesity with or without diabetes, revealed substantial and sustained weight loss that exceeded outcomes typically achieved with existing pharmacologic options
The decreased release of protective inflammatory factors, such as Arg-1 and CD206, and increased expression of proinflammatory markers, such as IL-6, iNOS, and TNF-, as well as metabolites like the -dicarbonyl and AGER pathways (98)
Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.